S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Biden, McCarthy to discuss debt limit in talks on Wednesday
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Biden, McCarthy to discuss debt limit in talks on Wednesday
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Biden, McCarthy to discuss debt limit in talks on Wednesday
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Biden, McCarthy to discuss debt limit in talks on Wednesday
NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$224.59
-7.58 (-3.26%)
(As of 01/27/2023 08:55 PM ET)
Add
Compare
Today's Range
$221.58
$235.53
50-Day Range
$205.07
$236.53
52-Week Range
$189.40
$262.38
Volume
1.18 million shs
Average Volume
717,011 shs
Market Capitalization
$32.90 billion
P/E Ratio
40.76
Dividend Yield
0.78%
Price Target
$263.17

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
17.2% Upside
$263.17 Price Target
Short Interest
Healthy
0.59% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.49mentions of ResMed in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$12.44 M Sold Last Quarter
Proj. Earnings Growth
12.95%
From $6.41 to $7.24 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

61st out of 1,049 stocks

Surgical & Medical Instruments Industry

6th out of 105 stocks


RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

ResMed (NYSE:RMD) PT Raised to $260.00
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
ResMed Inc. (NYSE:RMD) CEO Michael J. Farrell Sells 5,675 Shares
JPMorgan Chase & Co. Upgrades ResMed (NYSE:RMD) to Overweight
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Ex-Dividend for 12/15 Dividend
11/09/2022
Dividend Payable
12/15/2022
Last Earnings
1/26/2023
Today
1/30/2023
Ex-Dividend for 3/16 Dividend
2/08/2023
Dividend Payable
3/16/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
8,160
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$263.17
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+17.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
7 Analysts

Profitability

Net Income
$779.44 million
Pretax Margin
26.57%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$7.14 per share
Book Value
$22.97 per share

Miscellaneous

Free Float
144,448,000
Market Cap
$32.90 billion
Optionable
Optionable
Beta
0.50

Social Links


Key Executives

  • Dr. Peter C. Farrell A.M. (Age 81)
    AM, B.E., BE (Hons), Ph.D., ScD, Founder & Non-Exec. Chairman
    Comp: $430.56k
  • Mr. Michael J. Farrell BEMr. Michael J. Farrell BE (Age 51)
    MBA, SM, CEO & Director
    Comp: $2.66M
  • Mr. Robert A. Douglas (Age 63)
    Pres & COO
    Comp: $1.82M
  • Mr. Brett A. SandercockMr. Brett A. Sandercock (Age 56)
    Chief Financial Officer
    Comp: $891.39k
  • Mr. David B. PendarvisMr. David B. Pendarvis (Age 64)
    Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
    Comp: $1.11M
  • Mr. Kaushik Ghoshal (Age 55)
    Pres of SaaS Bus.
    Comp: $1.11M
  • Ms. Urvashi Tyagi
    Chief Technology Officer
  • Ms. Constance C. Bienfait
    Director of Investor Relations
  • Ms. Amy Wakeham
    VP of Investor Relations & Corp. Communications
  • Ms. Vered Keisar
    Chief People Officer













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

7 brokers have issued 12 month price objectives for ResMed's shares. Their RMD share price forecasts range from $245.00 to $280.00. On average, they anticipate the company's share price to reach $263.17 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 at the start of the year. Since then, RMD stock has increased by 7.9% and is now trading at $224.59.
View the best growth stocks for 2023 here
.

Are investors shorting ResMed?

ResMed saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 850,000 shares, a decrease of 15.8% from the December 31st total of 1,010,000 shares. Based on an average trading volume of 584,000 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.6% of the company's stock are short sold.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) issued its quarterly earnings results on Thursday, January, 26th. The medical equipment provider reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.04. The medical equipment provider earned $1.03 billion during the quarter, compared to analysts' expectations of $996.22 million. ResMed had a net margin of 21.51% and a trailing twelve-month return on equity of 26.18%. ResMed's revenue was up 15.5% compared to the same quarter last year. During the same period last year, the firm earned $1.47 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, January 26th. Investors of record on Thursday, February 9th will be paid a dividend of $0.44 per share on Thursday, March 16th. This represents a $1.76 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Wednesday, February 8th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.76%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.31% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.37%), Ardevora Asset Management LLP (0.15%), New York State Teachers Retirement System (0.11%), Capital Investment Services of America Inc. (0.09%), Natixis Advisors L.P. (0.08%) and Baillie Gifford & Co. (0.05%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $224.59.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $32.90 billion and generates $3.62 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.51 on an earnings per share basis.

How many employees does ResMed have?

The company employs 8,160 workers across the globe.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 1/30/2023 by MarketBeat.com Staff